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Abstract
Objective: This article reviews the current literature and knowledge about hepatosplenic T-cell
lymphoma (HSTCL), providing an overview of the clinical features, a description of its pathology and
immunophenotypic traits in relation to other lymphomas. In addition, we explore the history of
reported cases of hepatosplenic T-cell lymphoma in relation to the possible existence of a causal
relationship between infliximab use andHSTCL. The treatments for HSTCLwill be briefly addressed.
Methods: A comprehensive literature search using multiple databases was performed. Keyword
search phrases including “lymphoma,” “hepatosplenic T-cell lymphoma,” “Inflammatory bowel
disease,” “6-mercaptopurine,” and “infliximab” were used in various combinations. In addition
references from published papers were reviewed as well.
Results: There are over 200 reported cases of HSTCL. Only 22 cases of hepatosplenic T-cell
lymphoma are associated with IBD treatment. Clinicians usually reserve immunomodulators and
biologics for moderate to severe IBD cases. The ultimate goal of therapy is to control inflammation
and therefore allow mucosal healing. IBD patients demonstrating mucosal healing are less likely to
undergo surgery and experience complications related to their disease.Wemanipulate the immune
system with corticosteroids, immunomodulators, and biologics, therefore causing bone marrow
suppression. With bone marrow suppression, malignant degeneration may begin through selective
uncontrolled cell proliferation, initiating HSTCL development in the genetically susceptible.
Conclusion: Hepatosplenic T-cell lymphoma is a rare disease, often with a poor outcome. With the
increasing number of reported cases ofHSTCL linked to theuse of infliximab, adalimumab, andAZA/
6-MP, there appears to be an undeniable association of HSTCL development with the use of these
agents. This risk is unquantifiable. When considering the rarity of cases and the multiple
complications with uncontrolled disease, however, the benefit of treatment far outweighs the risk.
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For the last decade, hepatosplenic T-cell lymphoma (HSTCL)
was a relatively unknown disease. In fact, although it was in
1981 that Kadin and colleagues first recognized it as a distinct
entity from other peripheral T-cell lymphomas, the medical
world did not quite catch on to the significance of what HSTCL
entails.1 With the tantalizing hope of control and of relief for
patients suffering from inflammatory bowel disease (IBD) with
immunomodulating and biological agents, the rare disease of
HSTCL began to gain worldwide recognition. There are studies
that suggest an increased malignancy and lymphoma risk in
patients with IBD.2–4 But perhaps, a more specific question
would be whether lymphoma, including HSTCL, displays a
higher incidence in IBD patients who received immunomodu-
lating agents and/or biological agents. If so, are clinicians
putting their IBD patients at increased risk for HSTCL with the
use of these medications?
Between the years 2001 and 2005, 70,214 new cases of
non-Hodgkin's lymphoma (NHL) were diagnosed. In the
general population, the incidence of NHL is 17.2 per
100,000 individuals per year. Non-Hodgkin's lymphoma is
usually a diagnosis of the older population, with a peak in the
6th to 7th decade. The incidence of extranodal NHL is 5.0 per
100,000.5 In the National Cancer Institute's Surveillance,
Epidemiology, and End Results (SEER) Database, there are a
total of 34 reported cases between 1973 and 2005 of HSTCL,
a subtype of extranodal NHL. This equates to an incidence of
only 0.046 per 100,000 individuals or 1 case per 1088 patient
years. Among the 34 cases, 24 were men, and 10 were
women. The age breakdown is as follows: 4 patients were
less than the age of 19, 6 patients were in their 20s, 12
patients were in their 30s, 5 patients in their 40s, 2 patients
in their 50s, and 5 patients older than 60 years old.5
Hepatosplenic T-cell lymphoma is a rare and aggressive
extranodal form of non-Hodgkin's lymphoma that affects
predominantly men. In addition to hepatosplenic involve-
ment as its name suggests, HSTCL is also characterized by a
lack of lymphadenopathy, the presence of cytopenias, and
sinusoidal infiltration of the splenic red pulp, liver, and bone
marrow.6–8 HSTCL has a rapidly progressive course. The
mean time of diagnosis to death is less than 16 months.8–10
Since Farcet et al. proposed HSTCL as a separate entity from
other peripheral T-cell lymphomas, there has been approx-
imately 238 cases of HSTCL reported worldwide through
literature search.7,8,10–102Among the medical community, especially the pediatri-
cians, there is a growing concern that HSTCL is an emerging
disease of the young, especially of pediatric patients treated
with biologic agents. This fear may not be warranted. Of all
the reported cases (not including the SEER Database), only 25
cases of hepatosplenic T-cell lymphoma are associated with
IBD treatment. An overwhelming 73% of HSTCL were de novo.
The de novo group includes patients that were explicitly
stated as healthy, which entails lack of autoimmune
diseases, treatment with immunosuppressants, history of
transplant, or any other primary malignancies. Character-
istics of patients who developed HSTCL de novo, including
mean age, sex prevalence, presentation, histopathology,
and prognosis did not differ from the patients with some
degree of immunosuppression.10,16,17,20 The second largest
incidence (18%) is found in immunocompromised patients.
This group consists of patients with renal and heart
transplant, chronic steroid use, systemic lupus erythroma-
tosis, recurrent malarial infections, sickle cell anemia,
dermatomyositis, autoimmune hepatitis, and primary malig-
nancies such as Hodgkin's lymphoma, acute myelogenous
leukemia, and multiple myeloma. The third largest group of
HSTCL (10%) was found in IBD patients exposed to treatment
with immunomodulators and/or biologics (Fig. 1).
Other inflammatory and autoimmune diseases such as
peripheral and axial arthritis, Sjogren's disease, polymyosi-
tis, systemic sclerosis, dermatitis herpetiformis associated
with celiac disease, psoriasis, Hashimoto's thyroiditis have
not been linked to the development of HSTCL. But these
diseases have all been shown to have a higher risk of
developing non-Hodgkin's lymphoma compared to the gen-
eral population.103
The lack of association with HSTCL in these inflammatory
diseases may be explained by the fact that B lymphocytes,
not gamma–delta T cells, play a predominant role in
immunity in the periphery and joint space. The chronic
inflammation may be a factor in precipitating the malignant
degeneration of the B cells involved. Some studies suggest a
100-fold risk with developing diffuse large B-cell lymphoma
in individuals with the highest rheumatoid arthritis disease
severity when compared to patients with low global disease
activity.103 Sjogren's disease, systemic lupus erythematosus,
and celiac disease are also associated with large B-cell
lymphoma development.103 The specific associations with
each specific inflammatory disease have been review
elsewhere.103
Figure 1 Distribution of HSTCL cases.
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HSTCL affects predominantly adult men, with a median age
of 35 years, with an age range of 8 months to 68 years.8,10,23
Patients typically present with splenomegaly (96%), hepato-
megaly (77%), systemic B-type symptoms (high fevers, night
sweats, and weight loss) (70%), bone marrow involvement
(72%), and thrombocytopenia (89%).8,10,16 Even in patients
who have undergone a splenectomy, the severity of
thrombocytopenia increases with disease progression.
Other common presenting signs include concomitant anemia
or leukopenia with thrombocytopenia, elevated lactate
dehydrogenase (LDH), elevated liver enzymes, and symp-
toms of hepatitis.8,13,104 Atypical findings include lympho-
cytosis, peripheral blood infiltration by tumor cells, and
simultaneous involvement of other organs (Table 1).1053. Pathology
A majority of reported cases of HSTCL are of the gamma–
delta T-cell receptor subtype. Case reports of the alpha–
beta subtype have been described as well. The alpha–beta
subtype of HSTCL demonstrates a predominance in women,
but is very similar to the gamma–delta subtype in clinical
presentation, pathology, and cytogenetics.9,17 It is consid-Table 1 Clinical presentation (symptoms, laboratory
findings).
% Patients with involvement
Symptoms
Splenomegaly 97
Hepatomegaly 78
Systemic B symptoms 70
Lymphadenopathy Approximately 0
Lab findings
Bone marrow involvement 73
Thrombocytopenia 90
Anemia 85
Leukopenia 72
Elevated LDH 60
Elevated liver enzymes 46ered a subvariant of HSTCL according to the World Health
Organization (WHO) classification of lymphomas.9,10
T cells are vital to the proper function of cell-mediated
immunity. Specifically, gamma–delta T cells are a popula-
tion of T cells comprising 5% of the adult T-cell population
that are important to mucosal immunity. Gamma–delta T
cells display an affinity for the epithelial layer of the
intestines, skin, and red pulp of the spleen.106,107 A knockout
mice study involving γδ T cells, confirm the immunoregula-
tory role of γδ T cells at the intestinal epithelium.108
Furthermore, Nanno et al. suggest that γδ T cells are the key
for proinflammation in colitis. In the γδ T-cell knockout mice
group, less severe colitis, a reduction in the production of
proinflammatory proteins, and a decrease of neutrophilic
infiltration, were observed.108
Like other peripheral T-cell lymphomas, HSTCL may
demonstrate erythrophagocytosis.1,9 Erythrophagocytosis
by reactive tumor cells have been reported rarely.9,10,81
Pathological features include a significantly enlarged spleen,
with global infiltration of the splenic red pulp with atypical
lymphocytes.16 In the liver, there is a sinusoidal distribution
of tumor cells that may be accompanied by periportal and
portal invasion.8,105 The involved bone marrow is hypercel-
lular, and may include plasmocytosis and blood vessel
malformation.105 However, bone marrow infiltration is
often subtle and requires specific immunohistochemical
staining for T-cell antigens.105,109 Tumor cells are homoge-
nous and usually intermediate in size, but cells can vary in
size with each respective case. The bone marrow infiltration
pattern changes with disease progression, favoring an
interstitial spread over the characteristic sinusoidal pattern,
and tumor cells transform into larger cells, resembling
blasts.105,1094. Immunophenotypic traits
Cytometric immunophenotyping plays a central role in
confirming the diagnosis of HSTCL. Immunophenotyping has
been reviewed in detail.9,10,16,109 In contrast to the mucosal
and cutaneous gamma–delta T-cell lymphomas, hepatosplenic
T-cell lymphoma consists of atypical lymphocytes that are
cytotoxically inactive.6,16,109 This is exemplified by neoplastic
cells staining positive for T-cell restricted intracellular antigen
(TIA-1), and negative for granzyme B and perforin (proteins
released by cytotoxic T cells).16,109 The most common
immunophenotype of HSTCL is listed in Table 2. In order
to differentiate between the gamma–delta and alpha–beta
T-cell receptor (TCR) chains, monoclonal antibodies specific
to each chain are used.10 With other non-hepatosplenic
gamma–delta T-cell lymphomas, there is a strong association
with Epstein-Barr virus (EBV).110 Interestingly, the presence of
EBV infection in tumor cells of HSTCL patients, detected by in
situ hybridization for EBV- encoded small RNA (EBER), is
extremely atypical and therefore rarely seen.9,10,15,18,84
Cytogenetic analysis reveals the abnormality isochromo-
some 7q to be present consistently in all atypical lymphoid cells
of HSTCL.86,97,109 There have been recent reports of ring
chromosome7, a clonal aberration of 7q, inHSTCLpatients.25,47
Both chromosomal abnormalities lead to an amplification of the
long arm of Chromosome 7 therefore the amplification of
oncogenes, and varying degrees of 7p deletion, the location of
Table 2 Most common immunophenotypic traits.
Positive (+)/negative (−)
Cytolytic granule proteins
TIA-1 +
Granzyme B −
Perforin −
Natural killer cell associated
CD16 +/−
CD56 +
CD57 −
T cell associated
CD2 +
CD3 +
CD4 −
CD5 −
CD7 +/−
CD8 −
CD16 +/−
CD25 −
CD30 −
CD38 +
Epstein-Barr virus −
514 A. Thai, T. Prindivilletumor suppressor genes.69 Other defects include trisomy 8 and
loss of the Y chromosome.10,86,91,97
5. Treatment of HSTCL
Hepatosplenic T-cell lymphoma is a rapidly progression
disease with a mean survival of less than 16 months,
regardless of the treatment modality. Multiple treatment
modalities have been used, including cyclophosphamide,
doxorubicin, vincristine and prednisone (CHOP), CHOP-like
therapies, interferon alpha therapy, splenectomy, platinum
based chemotherapy, and allogeneic or autologous bone
marrow or stem cell transplantation. None are curative and
rarely is complete remission accomplished and sus-
tained.7,8,10 Individual case reports on HSTCL treatment
seem promising. Jaeger and colleagues recently documented
complete remission in a HSTCL patient with Rituximab with
CHOP, followed by a combination of alemtuzumab and
cladribine for a total of 27 months.29 Rituximab selectively
binds to CD20, a marker for both malignant and normal B
cells. In the patient mentioned above, the immunopheno-
typic trait included being CD20 positive.29 This example
serves to emphasize that HSTCL's immunophenotype may
vary from patient to patient. Therefore it may be beneficial
to tailor treatment to each individual case according to
immunophenotypic traits.
6. HSTCL and IBD treatment
Immunosupression with corticosteroids, cyclosporine, inflix-
imab, adalimumab, azathioprine, and 6-mercatopurine have
been associated with HSTCL.10,13,14,32,111 In addition, many
HSTCL cases are linked to alterations or deficits in the
immune system exemplified by cases in severe immunode-
ficiency disorders, multiple recurrent malarial infections,and pregnancy.21,23,24 There is an obvious association
between immunosuppression and the development of
HSTCL. By manipulating the immune response of IBD patients
with medications, there may be an increased chance of
developing HSTCL.
The efficacy of corticosteroids and thiopurine therapy
with azathioprine and 6-mercaptopurine in IBD has been well
established. But there are risks that come with using these
medications. One major concern is the increased incidence
of lymphoma. A meta-analysis performed by Kandiel and
colleagues suggests that the risk of lymphoma in IBD patients
treated with AZA or 6-MP is four times the risk of the general
population.112 However, a confounding factor to the study
may include the severity of the disease in relation to the
population of IBD patients who actually receive immunomo-
dulating treatment. Preliminary results from a French cohort
study involving 20,802 IBD patients suggest an increased risk
for development of lymphoma especially with AZA use.113
Disanti et al. performed a study that examined the
lymphoma incidence in IBD patients with 6-MP induced
sustained leukopenia. Their findings indicate that patients
on 6-MP treatment that developed sustained leukopenia,
defined as leukocyte count of less than or equal to 4000 for a
total of ≥20 days, had a statistically significant higher
incidence of lymphoma (7%) even after confounding factors
were accounted for.114 The exact cause of this leukopenia
leaves room for discussion. It is unlikely that the sustained
leukopenia is a result of overdosing. The observed leukope-
nia is likely the result of the unmasking of a preleukemic
state already present in the host's bone marrow.
Early studies suggest that 6-MP and thioguanine metabo-
lites cause immunosuppresion and cytotoxicity by inhibiting
purine synthesis through direct binding to guanine triphos-
phate. However, Tiede and colleagues propose that the
mechanism of action is through the inhibition of Ras-related
C3 botulinum toxin substrate 1a (Rac1), a GTP-binding
protein.115 They demonstrate that the 6-MP metabolite, 6-
thioguanine triphosphate binds to Rac1 directly. Even at low
concentrations of AZA, Rac1 inhibition along with costimula-
tion of CD28 leads to apoptosis.115 6-thioguanine nucleotide
(6-TGN) levels closely correlate with therapeutic efficacy
and myelotoxicity.116 Approximately 5% of patients treated
with AZA or 6-MP may not develop apoptosis, and are
considered drug failures and possibly have a phosphorylation
defect.
Immunomodulator use is usually reserved for moderate to
severe disease. Clinicians generally utilize a milligram per
kilogram approach or a dosage regimen tailored through
monitoring 6-MP metabolites. Most clinicians traditionally
start at low doses and slowly titrate up the administered
dosage according complete blood counts, closely monitoring
for myelotoxicity and adverse reactions.
Pharmacogenomic studies of thiopurine metabolism re-
veal a metabolite range from 230 to 400 for optimal
therapeutic benefit.116 In theory, if the magnitude of 6 TG
binding to nucleotides is important for oncogenesis then
traditional dosing at milligram per kilograms (mg/kg) and
observing for leukopenia may expose the patient to more
risk.
Accomplishing the desired therapeutic response, while
protecting the patient's safety, may prove to be difficult.
Given the narrow therapeutic index balanced with the
515Hepatosplenic T-cell lymphoma development in IBDpharmacokinetic variability determined by genetics, it may
be safer to individualize, and therefore optimize therapy
according to TPMT genotyping and metabolite levels.116,117
The genotype profiles and recommendations for metabolite
level monitoring have been reviewed in detail elsewhere.116
Multiple studies, such as the ACCENT trials and ACT trials,
demonstrated infliximab to be beneficial in controlling
active mucosal inflammation and in maintaining remission
in IBD.118–120 There is conflicting evidence for the association
of infliximab use and increased risk for lymphoma. When
Wolfe and colleagues performed a study including 18,572
patients with rheumatoid arthritis, a causal relationship
between infliximab use and development of lymphoma could
not be established.121 In a multicenter-matched study,
Biancone and colleagues revealed that there is no data
supportive of a causal relationship between infliximab use
and development of malignancy.122 Only nine out of 404
patients treated with infliximab developed cancer, including
3 cases of breast adenocarcinoma, 1 laryngeal carcinoma, 1
basal cell carcinoma, 1 cholangiocarcinoma, 2 cases of rectal
carcinoma, and 1 case of leukemia. The incidence of
malignancy was comparable to the control group that had 7
cases of malignancy out of 404 patients.122 A meta-analysis
of anti-TNF therapy in patients with rheumatoid arthritis
(RA) which included nine randomized control trials, sug-
gested an increased risk of malignancy with anti-TNF therapy
that was dose dependent.123 The majority of the patients
developed malignancy early during treatment, with 19/34
patients diagnosed with new malignancy within 20 weeks of
starting treatment. This suggests that a number of these
newly diagnosed malignancies may represent preexisting
cancers. This study also contradicts findings from a Swedish
population based study which concluded that there was no
increased risk of solid malignancies in patients treated with
anti-TNF therapy with RA compared to other RA patients.124
Of note, there have been a total of 19 cases of HSTCL
linked to infliximab use and 4 cases linked to the use of
adalimumab (Table 3).111 Of the 19 infliximab cases, only 4
cases involved patients ≤18 years old. Along with exposure
to biologics, each patient received either AZA, 6-MP, or
prednisone at some point during their respective treatment
course. There are 6 reported cases of HSTCL in patients who
had no prior exposure to biologics, (3 cases with AZA,
sulfasalazine and/or prednisone, 1 case with AZA mono-
therapy, 1 case with AZA and unknown IBD therapy, 1 case
with 6-MP exposure).16,19,22,125,126 As mentioned previously
there could be many factors playing into the development of
HSTCL in IBD patients treated with biological agents. It
appears that factors including severity of IBD in patients who
ultimately receive biologic therapy, the possibility of dose-
related effect, the differences in each patient's innate
immune response and therefore varying degrees of immuno-
suppression accomplished by biologics, may singularly or
collectively contribute to HSTCL development. Perhaps, a
synergistic or catalystic effect of dual therapy with
immunomodulators and biological agents propels a malig-
nant degeneration and thus the development of HSTCL.
If one decides to incorporate biologics and immunomo-
dulating therapy, the risk of inducing HSTCL is there. How
should clinicians approach IBD patients in relation to
treatment with immunomodulators, anti-TNF therapy, or a
combination of both? There is a clear benefit to treating IBDpatients with immunomodulators and anti-TNF therapy to
control disease progression. Lewis and colleagues demon-
strated an increased quality-adjusted life expectancy,
measured by the Crohn's Disease Activity Index (CDAI), in
Crohn's patients using azathioprine to maintain disease
remission.127 Although there have been case reports of
patients developing HSTCL after being treated with immu-
nomodulating and biological agents, it is still relatively rare.
Recent preliminary results from the Study of Biologic and
Immunomodulator Naïve Patients In Crohn's Disease (SONIC)
trial, give tangible hope to controlling inflammatory bowel
disease with both immunomodulators and biologics.128 IBD
patients treated with both AZA and infliximab demonstrated
an overwhelming response with 56.8% maintaining cortico-
steroid-free clinical remission at Week 26. More significant-
ly, at 26 weeks a large proportion of patients on dual therapy
displayed mucosal healing.128 The presence of mucosal
healing signifies a significant decrease in active inflamma-
tion and successful regeneration of normal mucosa.129
Mucosal healing is a favorable prognostic indicator of disease
activity. IBD patients demonstrating mucosal healing are less
likely to undergo surgery and experience complications
related to their disease.130,131 More long-term studies need
to be done in order to further determine if there is a causal
relationship with biologics and HSTCL.
Delineating the exact mechanisms for malignant degen-
eration is important for understanding the observed link
between IBD and HSTCL. It is well known that chemicals,
medications, viruses, radiation, and rapid cell turnover
initiate neoplastic transformation. A disruption in the cell
cycle check points either through alterations in tumor
suppressor genes and proto-oncogenes, or the DNA sequence
itself, changes cell signal transduction. Patients with IBD
experience chronically active inflammation, initiating con-
stant cell regeneration and rapid turnover. Treatment with
immunomodulators and biologics may be the epigenetic
factor that allows selective uncontrolled cell proliferation
and therefore initiate HSTCL development in the genetically
susceptible. But why is HSTCL so rapidly progressive? It could
be that a latent viral infection had the opportunity to
permanently alter the RNA/DNA sequence previously. The
immunosuppressing agents could be the jump start needed
to complete the process. Continued research in this area may
lead to the answer, as the exact mechanisms remain
unknown.
When formulating an IBD treatment plan, factors to
consider in each patient's case include the severity of
patient's disease, history of intolerable side effects from
specific agents, history of failure of specific therapy, and the
patient's decision after knowing the benefits and reported
risks of each class of drugs.132–1347. IBD treatment strategies
The third largest group of patients with HSTCL was found in
IBD patients exposed to treatment with immunomodulators
and/or biologics. This makes up only 10% of all reported
cases. Regardless of the rarity of these cases, the increased
risk of HSTCL development is present. This risk further
complicates the clinical management of patients with
moderate to severe inflammatory bowel disease, especially
Table 3 Cases of HSTCL associated with IBD treatment.
Therapy exposure
Case
#/reference
Age/
sex
IBD
Dx
HSTCL subtype A AZA/6-MP Infliximab and AZA/6-MP Other Tx
116 ? UC −γ/δ AZA 17 yrs ?
222 35 M CD −γ/δ, Isochromosome 7q,
Trisomy 8
AZA 5.6 yrs – Sulfasalazine
– Steroid for 10 yrs
319 18 M CD −γ/δ AZA 6 yrs ?
4126 ? CD Unknown AZA 4 yrs − Prednisone
− IV Cyclosporine
511 30s M CD −γ/δ 6-MP
6125 15 M UC Unknown AZA 9 yrs − Sulfasalazine
− Prednisone
713 17 F CD −α/β 6-MP 4.5 yrs
Infliximab: 20 doses of 5 mg/kg
− Prednisone
− Mesalamine
8135 31 M CD −γ/δ, Isochromosome 7q 6-MP 5 yrs
Infliximab: 3 doses of 300 mg
− Mesalamine
− Prednisone
9111 19 M CD −γ/δ AZA 7 yrs Infliximab: 3 doses of
300 mg/kg
None
10111 18 M CD −γ/δ, Isochromosome 7q AZA 5 yrs, 6-MP
Infliximab: 5 doses of 5 mg/kg
− Prednisone,
budesonide
11111 19 M CD −α/β AZA 6 yrs, 6-MP
Infliximab:14 doses of 550–600 mg
− Mesalamine
− Prednisone
12111 12 M CD −γ/δ, Isochromosome 7q AZA 4 yrs, 6-MP
Infliximab: 21 doses of 300 mg
− Mesalamine
13111 15 M CD −γ/δ, Isochromosome 7q AZA 2.5 yrs
Infliximab:13 doses of 150–200 mg
− Mesalamine
− Prednisone
14111 31 M CD −γ/δ 6-MP 3 yrs
Infliximab: 1 dose of 5 mg/kg
– Mesalamine
− Prednisone
− MTX
15111 22 M CD −α/β, Trisomy 13 6-MP 4 yrs
Infliximab: 24 doses of 5 mg/kg
− Mesalamine,
Basalazide
− Prednisone
16111 22 M IC −γ/δ AZA 5 yrs
Infliximab: 1 dose of 5 mg/kg
− Mesalamine
− Steroids
17111 31 M CD −α/β, Trisomy 8, loss of
chromosome y, 7p deletion
AZA 5 yrs
Infliximab: 3 doses of 5 mg/kg
− Sulfasalazine
− Prednisolone
18111 40 M CD −γ/δ AZA 7 yrs
Infliximab: 3 doses of 5 mg/kg
− Prednisone
19111 21 M UC Unknown 6-MP 7 yrs
Infliximab: ? doses of 5 mg/kg
– Mesalamine
− Adalimumab
20111 19 M CD Unknown, Isochromosome 7q 6-MP
Infliximab: 18 doses of 5–10 mg/kg
− Mesalamine
− Prednisone
21111 29 M CD −γ/δ AZA 11 yrs
Infliximab: 3 doses of 400 mg
− Adalimumab
22111 58 M CD Unknown −AZA,
unknown
duration
−NO infliximab history − Adalimumab
CD, Crohn's disease; UC, ulcerative colitis; IC, indeterminate colitis; Dx, diagnosis; yrs, years.
516 A. Thai, T. Prindivillein the pediatric population. The current clinical opinion is
that there is an increased risk of HSTCL development
associated with the use of immunomodulators and biologic
agents. However, the good news is approximately one million
patients have received this medication over time and
throughout that time interval, a progressive increase in
HSTCL has not been observed. When the first cases of HSTCL
associated with immunomodulator use were reported, mostpediatricians immediately stopped using 6-MP, and imple-
mented infliximab monotherapy. In the survey conducted by
Cucchiara et al. for the European Society for Pediatric
Gastroenterology, Hepatology, and Nutrition (ESPGHAN),
97% of pediatric patients with Crohn's Disease were treated
with immunomodulators and infliximab before the year of
2007. This number significantly dropped when case reports
revealed Crohn's patients on combined immunomodulator
517Hepatosplenic T-cell lymphoma development in IBDand infliximab therapy may have an increased risk of
developing HSTCL. Among the clinicians surveyed, only one
third of the pediatricians were still using thiopurines. Most
changed their management to include either monotherapy
with infliximab, or combined therapy with methotrexate and
infliximab.136Pediatricians at our institution are starting to
use 6-MP with infliximab again.
An important question, without a clear guideline estab-
lished on objective data, remains. What is the best approach
in utilizing immunomodulators and biologics that would
guarantee optimal patient outcomes? There are multiple
treatment algorithms available in regards to the treatment
of moderate to severe IBD. The plan of treatment often
reflects philosophical differences depending on the institu-
tion one trained in or practices in. More importantly, an
individual physician's treatment goals or end points, whether
it be symptomatic control and/or mucosal healing, preven-
tion of immunogenicity, or increasing the therapeutic
response to biologic therapy, often dictate the treatment
plan. Treatment strategies include monotherapy with
biologics or immunomodulators, the use of immunomodula-
tors in concomitant therapy or in bridging therapy, and early
aggressive therapy with both agents (the “top–down
approach”). There is clinical evidence that support and
challenge the methods listed above.
The use of immunomodulators and corticosteroids repre-
sent the traditional approach before the introduction of
biologics. The disadvantage of this approach evolved around
the effects of corticosteroids. However, the most recent
SONIC trial reveals that a small percentage of patients will
respond with immunomodulator therapy with modest muco-
sal healing.128 This category of therapy in this study provides
a reference point to compare various treatment strategies in
terms of response and mucosal healing.
Results from a multi-center randomized control trial,
suggest that monotherapy with infliximab was just as
effective in controlling disease, as measured by mucosal
healing and clinical scores (Crohn's Disease Activity Index
[CDAI] and Inflammatory Bowel Diseases Questionnaire
[IBDQ]), as was concomitant therapy with immunosuppres-
sives and infliximab.137However, Van Assche et al., also
discovered that patients on monotherapy had lower inflix-
imab trough levels, corresponding to higher C-reactive
protein levels and higher clinical scores. In addition, it
appears that over time, patients on monotherapy developed
immunogenicity, as indicated by the increase in patients
requiring adjustments to dosing schedules, the development
of intolerance, and the loss of response.137If the treatment
goal is to effectively inhibit immunogenicity, then concom-
itant therapy with immunomodulators may be the answer.
Concomitant therapy inhibits the formation of antibodies to
infliximab (ATIs), resulting in higher infliximab trough levels
and therefore an improved therapeutic response.128,138–140
Bridging therapy or induction of clinical remission with
infliximab followed by maintenance with immunomodulators
alone, has advantages. A two year open-label randomized
control trial in Belgium compared the effectiveness of
bridging therapy with the conventional treatment regimen,
which included sequential addition of corticosteroids,
azathioprine, and infliximab.141 All 133 Crohn's patients
were naïve to treatment with steroids, immunosuppressing
agents (methotrexate or azathioprine), and biologic agents.This study proved that bridging therapy was superior to the
conventional “step-up” therapy. Sixty percent of patients
who received early combined therapy with 3 infusions of
infliximab with azathiopurine, who were then maintained on
azathioprine alone, demonstrated clinical remission at 26
and 52 weeks. This significant level of remission is in contrast
to 35.9% and 42.2% of the patients who were randomized to
conventional therapy, at 26 and 52 weeks respectively. In
addition they found that patients who were bridged to
immunosuppressive therapy, had a significant rapid reduc-
tion in C-reactive protein levels by week 10, as well as more
ulcer free patients (73.1%) at week 104.141 Further investi-
gations on bridging therapy are of interest, as there is a
concern of the cost effectiveness of the use of biological
agents.
Early aggressive therapy is supported by multiple studies.
The SONIC trial makes a strong argument for the benefits of
concomitant therapy and early aggressive therapy in Crohn's
disease.128 Early aggressive therapy with infliximab and
azathioprine maintained corticosteroid-free clinical remis-
sion and resulted in the best mucosal healing.128Most data on
the use of early aggressive therapy in inflammatory disease
processes can be found in large randomized prospective
rheumatoid arthritis trials. There are multiple randomized
control trials involving the concomitant use of anti-TNF
inhibitors with immunomodulators compared to monother-
apy that demonstrate an enhanced clinical response with
greater improvements in functionality and quality of life, as
well as prevention of the progression of joint destruction or
erosions.142–148 A recent study performed by Emery et al.
found that combination therapy with golimumab and
methotrexate in methotrexate and anti-TNF naïve patients,
was more efficacious than monotherapy with either meth-
otrexate or adalimumab, in achieving better clinical re-
sponse rates.148
The best control of immunogenicity was with oral
methotrexate and remicade in the initial RA trial with a
resultant 8%.149 Additionally, the immunogenicity was very
low with concomitant therapy in the SONIC trial of 0.9%.128
HSTCL has not been reported with the use of methotrexate.
However, oral methotrexate therapy has not been proven to
work with Crohn's disease. The incidence of immunogenicity
with sporadic therapy was 30% in the 54 week Crohn's disease
trial.119
Early aggressive therapy in RA altered the natural history
of the disease. This change is easier to demonstrate in RA
compared to CD secondary to scoring systems and objective
measurements of disease progression, i.e. joint destruction.
Bridging therapy and early aggressive therapy in CD suggests
that these therapies may change the natural history of this
disease. Multi-center randomized trials will be needed to
further define the evolving philosophical approaches and end
points for therapy.8. Conclusion
Hepatosplenic T-cell lymphoma is a rare disease, often with
a poor outcome. With the increasing number of reported
cases of HSTCL linked to the use of infliximab, adalimumab,
and AZA/6-MP, there appears to be an undeniable associa-
tion of HSTCL development with the use of these agents. But
518 A. Thai, T. Prindivilleunfortunately, this risk is not quantifiable. But with its
presence, both patients and clinicians may need to think
twice about controlling IBD with these agents. When
considering the rarity of cases and the multiple complica-
tions with uncontrolled disease, however, the benefit of
treatment far outweighs the risk. A more prudent approach
to the treatment and management of IBD patients, may just
be to stick to the fundamentals of the practice of medicine:
combine clinical experience, established evidence based
guidelines, and meticulous consideration into each individual
patient's case.
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